Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study
Authors:
Open Access
- 21 July 2025
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-11
Abstract
Despite concurrent chemoradiotherapy (CCRT) being the standard treatment for locally advanced nasopharyngeal carcinoma (NPC), there remains considerable variability in survival outcomes among patients with the same tumor-node-metastasis (TNM) staging. This study aims to evaluate the prognostic significance of the pretreatment Pan-Immune-Inflammation Value (PIV), an integrative marker of immune-inflammatory status, in NPC patients undergoing CCRT. A total of 860 NPC patients treated with platinum-based CCRT were included in this retrospective study. PIV was derived from pretreatment peripheral blood counts, categorizing patients into high-PIV (> 244.4) and low-PIV (≤ 244.4) cohorts. Overall survival (OS) rates were estimated using Kaplan-Meier methods and analyzed through Cox proportional hazards models. A PIV-based prognostic nomogram was developed and subsequently validated. Patients classified with low PIV exhibited markedly improved OS compared to those with high PIV (HR = 0.559, 95% CI: 0.415–0.753, P < 0.001). In the multivariate analysis, PIV emerged as an independent prognostic indicator, alongside age, T stage, N stage, and body mass index (BMI). Furthermore, the PIV-based nomogram demonstrated enhanced prognostic accuracy (C-index: 0.680, 95% CI: 0.641–0.719) when contrasted with the traditional TNM staging system (C-index: 0.638, 95% CI: 0.573–0.703). The pretreatment PIV serves as an independent prognostic factor in NPC patients receiving CCRT. The nomogram founded on PIV offers improved prognostic capacity over conventional TNM staging, thereby holding potential in guiding personalized treatment strategies for this patient demographic.Keywords
This publication has 60 references indexed in Scilit:
- A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter AnalysisTargeted Oncology, 2023
- Pan-immune inflammation value; a novel biomarker reflecting inflammation associated with frailtyAging Clinical and Experimental Research, 2023
- Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinomaEBioMedicine, 2022
- Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal CarcinomaJAMA, 2022
- The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaCancer Communications, 2021
- A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: A multicentre studyEBioMedicine, 2021
- Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistanceDrug Resistance Updates, 2020
- Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinomaHead & Neck, 2018
- A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapyCancer, 2016
- A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinomaCancer, 2000